Who are Ethynyl estradiol and Drospirenone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ethinyl Estradiol-cyprosterone acetate, ParaGard®, Ethinylestradiol / Dienogest, ETHINYL ESTRADIOL AND LEVOGESTREL, Subcutaneous depot medroxyprogesterone acetate, Drospirenone and Ethinyl Estradiol tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ethynyl-estradiol-and-drospirenone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ethynyl estradiol and Drospirenone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ethynyl estradiol and Drospirenone (Ethynyl estradiol and Drospirenone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: contraceptive. Area: Women's Health.

phase 2 contraceptive Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

Ethynyl estradiol and Drospirenone (Ethynyl estradiol and Drospirenone) — Ospedale Policlinico San Martino. Ethynyl estradiol and drospirenone work by inhibiting ovulation and thickening cervical mucus to prevent sperm penetration.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ethynyl estradiol and Drospirenone TARGET	Ethynyl estradiol and Drospirenone	Ospedale Policlinico San Martino	phase 2	contraceptive
Ethinyl Estradiol-cyprosterone acetate	Ethinyl Estradiol-cyprosterone acetate	S.C.B. Medical College and Hospital	marketed	Oral contraceptive; combined estrogen-progestin	Estrogen receptor; progesterone receptor; androgen receptor (antagonist)
ParaGard®	ParaGard®	FHI 360	marketed	Intrauterine contraceptive device (copper IUD)	Copper ion-mediated spermicidal and anti-implantation effects
Ethinylestradiol / Dienogest	Ethinylestradiol / Dienogest	University of Palermo	marketed	Combined oral contraceptive	Estrogen receptor, progesterone receptor
ETHINYL ESTRADIOL AND LEVOGESTREL	ETHINYL ESTRADIOL AND LEVOGESTREL	FHI 360	marketed	Combined oral contraceptive	Estrogen receptor and progesterone receptor
Subcutaneous depot medroxyprogesterone acetate	Subcutaneous depot medroxyprogesterone acetate	Planned Parenthood Federation of America	marketed	Progestin contraceptive	Progesterone receptor
Drospirenone and Ethinyl Estradiol tablets	Drospirenone and Ethinyl Estradiol tablets	Hansoh BioMedical R&D Company	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (contraceptive class)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2 drugs in this class
Ospedale Policlinico San Martino · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ethynyl estradiol and Drospirenone — Competitive Intelligence Brief. https://druglandscape.com/ci/ethynyl-estradiol-and-drospirenone. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab